Potency Assays for ATMPs – Conception, Development, Validation, Matrixed Approaches and Assay Lifecycle
Complete the form to view the recording.Share this resource:
Now Streaming On-Demand
Advanced therapy medicinal products or ATMPs, are among the fastest growing areas of biotherapeutics, encompassing gene therapies, viral therapies, vaccines and cell therapies. The control strategies are very different from more traditional biologics, with quantitation of potency posing one of the greatest challenges. In this webinar, representative case studies will demonstrate considerations in the conception, development and validation of potency assays — mostly cell-based — for representative ATMPs. The use of different analytical technologies and complex assay schema will be provided along with consideration of timing, phase-appropriate validation (qualification) considerations and assay lifecycle guidance as the product moves through the clinical development phases.
About the Speakers
Jeff Patrick, Ph.D., Senior Director of GMP Operations, has served as Senior Director of GMP Operations at BioAgilytix in Durham, NC for three years. Prior to that, he served as Associate Director of the CMC group at Covance in Greenfield, IN for four years, and earlier held several positions in biologics development over 20 years. These roles included leadership in process analytical development, CMC, analytical development, early phase discovery and manufacturing of biologics. Jeff also applied his expertise in metabolomics, proteomics and biomarker utilization to the development of biologics. He has published more than 30 papers and reviews and earned his Ph.D. from Purdue University in analytical chemistry and an M.S. in chemistry from the University of South Carolina.
Lynn Kamen, Ph.D., Scientific Officer, Executive Director, earned her Ph.D. in Immunology at the University of Michigan and completed a postdoctoral fellowship at the University of California San Francisco. She has spent the past decade working in drug development supporting both large and small molecule formats from early target discovery through clinical development. Most recently, she was a principal scientist at Genentech where she supported large molecule and novel modality bioanalysis including PK, immunogenicity and biomarker.